You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 1200 A clinically validated pH-sensitive nanomedicine platform for encapsulating therapeutic bispecific T cell engagers for tumor specific delivery and activation

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immuno-Conjugates and Chimeric Molecules
1200 A clinically validated pH-sensitive nanomedicine platform for encapsulating therapeutic bispecific T cell engagers for tumor specific delivery and activation
Free

Authors

Citation

Gutowski S, Su Q, Burcham A, et al
1200 A clinically validated pH-sensitive nanomedicine platform for encapsulating therapeutic bispecific T cell engagers for tumor specific delivery and activation
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1200

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.